Table 2 Demographics of the unique individuals and ORs for the familial risk of having a EULAR response at 3 and 6 months, as well as being persistent at 1 and 3 years given a family history of persistence, both in a cohort of Swedish early RA patients diagnosed 1999–2019, treated with MTX in monotherapy as their first prescribed DMARD and with a first-degree relative concordant for early RA and treatment with MTX in DMARD monotherapy; stratified by response and persistence status respectively, for those included in the analysis
From: Does persistence to methotrexate treatment in early rheumatoid arthritis have a familial component?
EULAR response | Family history | |||||||
|---|---|---|---|---|---|---|---|---|
EULAR response at 3 months | EULAR response at 6 months | Persistence at 1 year | Persistence at 3 years | |||||
Good or moderate responders, N = 156 | Non-responders, N = 62 | Good or moderate responders, N = 116 | Non-responders, N = 92 | Persistent, N = 108 | Non-persistent, N = 50 | Persistent, N = 56 | Non-persistent, N = 63 | |
Female (%) | 107 (69%) | 49 (79%) | 77 (66%) | 71 (77%) | 74 (69%) | 36 (72%) | 36 (64%) | 47 (75%) |
Seropositive (%) | 117 (76%)a | 50 (81%) | 87 (77%)a | 67 (74%)c | 73 (70%)a | 34 (69%)c | 38 (70%)b | 43 (69%)c |
Glucocorticoids at baseline (%) | 74 (48%) | 31 (47%) | 65 (57%) | 38 (40%) | 54 (50%) | 17 (34%) | 23 (41%) | 31 (49%) |
Mean age at the start of MTX (SD) | 58 (14) | 52 (15) | 57 (15) | 54 (15) | 61 (14) | 52 (14) | 63 (13) | 54 (15) |
Median year of the start of MTX (Q1–Q3) | 2011 (07–15) | 2011 (05–15) | 2010 (06–14) | 2010 (05–15) | 2015 (11–17) | 2015 (13–17) | 2016 (14–18) | 2015 (12–17) |
Median overall number of FDRs (Q1–Q3) | 4 (3–5) | 4 (3–5) | 4 (3–5) | 4 (3–5) | 4 (3–5) | 4 (3–4) | 4 (3–5) | 4 (3–5) |
OR (95% CI) | 0.60 (0.23–1.58) | 0.71 (0.36–1.41) | 0.89 (0.41–1.94) | 1.42 (0.66–3.07) | ||||